# Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Source: https://onco.cc/trials/nct04373369/  
OnCo record `nct04373369` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Vorolanib and Atezolizumab in Extensive-stage small-cell lung cancer, run by Washington University School of Medicine, recorded as terminated on the registry.

## Summary

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer is a phase 2 interventional study registered as NCT04373369 by Washington University School of Medicine, with 11 participants recorded, started 2020-10-07 and due to reach its primary completion in 2022-08-18. Interventions recorded: Vorolanib, Atezolizumab. Conditions recorded: Extensive-stage Small Cell Lung Cancer.

Linked to the drug Vorolanib because the registry names it among its interventions and Extensive-stage small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04373369
- Phase: 2
- Setting: A Phase II Study of Maintenance Vorolanib and Atezolizumab in Patients With Extensive-stage SCLC
- Sponsor: Washington University School of Medicine
- Enrolled: 11

## Sources

- ClinicalTrials.gov NCT04373369: https://clinicaltrials.gov/study/NCT04373369

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Vorolanib](https://onco.cc/drugs/vorolanib/)

---
JSON: https://onco.cc/api/v1/entities/nct04373369.json